Biomea Fusion doses first patient in phase II diabetes studies
Go back to Biomea Fusion doses first patient in phase II diabetes studies| (NASDAQ: BMEA) | Delayed: 1.23 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.23 | 52 Week High | $ | |||
| Open | $1.23 | 52 Week Low | $ | |||
| Day High | $1.29 | P/E | N/A | |||
| Day Low | $1.22 | EPS | $ | |||
| Volume | 435,184 | |||||
